NCT05358106View on ClinicalTrials.gov

Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

December 5, 2022

Study Completion Date

April 2, 2023

Conditions
BK Virus Nephropathy
Interventions
BIOLOGICAL

AntiBKV

AntiBKV neutralising antibody

BIOLOGICAL

Placebo

Solution with no active ingredients

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
lead

Memo Therapeutics AG

INDUSTRY

NCT05358106 - Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers. | Biotech Hunter | Biotech Hunter